We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

202 hedge funds and large institutions have $753M invested in ARS Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

294% more call options, than puts

Call options by funds: $2.1M | Put options by funds: $532K

64% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 25

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

7% more funds holding

Funds holding: 189 → 202 (+13)

4.18% more ownership

Funds ownership: 90.01% → 94.19% (+4.2%)

9% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 56

27% less capital invested

Capital invested by funds: $1.04B → $753M (-$283M)

Holders
202
Holders Change
+13
Holders Change %
+6.88%
% of All Funds
2.49%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
41
Increased
61
Reduced
56
Closed
25
Calls
$2.1M
Puts
$532K
Net Calls
+$1.56M
Net Calls Change
+$1.05M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$27M
2
RCMNY
Rubric Capital Management (New York)
New York
+$17.3M
3
ACM
ADAR1 Capital Management
Texas
+$9.51M
4
TCM
Tyro Capital Management
Florida
+$9.33M
5
Franklin Resources
Franklin Resources
California
+$7.05M

Top Sellers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
-$18.6M
2
SCA
Southpoint Capital Advisors
New York
-$17.5M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$7.5M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.88M
5
LCG
Lisanti Capital Growth
New York
-$4.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
SPIA
51
Steward Partners Investment Advisory
New York
$1.18M -$669K -69,843 -32%
DCM
52
DAFNA Capital Management
California
$1.12M -$487K -50,780 -27%
EP
53
Eversept Partners
New York
$1.09M -$1.11M -115,358 -46%
WC
54
Wexford Capital
Florida
$1.05M -$335K -35,000 -21%
KOCAA
55
Knights of Columbus Asset Advisors
Connecticut
$1.04M -$6.68K -697 -0.5%
Rafferty Asset Management
56
Rafferty Asset Management
New York
$945K +$19.8K +2,071 +2%
Squarepoint
57
Squarepoint
New York
$918K +$1.1M +114,273 New
Swiss National Bank
58
Swiss National Bank
Switzerland
$861K – – –
Marshall Wace
59
Marshall Wace
United Kingdom
$843K +$247K +25,792 +33%
QCM
60
Quantinno Capital Management
New York
$814K +$463K +48,299 +91%
ECM
61
ExodusPoint Capital Management
New York
$772K +$921K +96,093 New
SIA
62
Sit Investment Associates
Minnesota
$746K – – –
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$700K – – –
SAM
64
Sectoral Asset Management
Quebec, Canada
$677K +$473K +49,347 +166%
Barclays
65
Barclays
United Kingdom
$676K -$1.08M -112,218 -57%
VFIC
66
Valley Forge Investment Consultants
Pennsylvania
$668K – – –
Corient Private Wealth
67
Corient Private Wealth
Florida
$650K +$776K +80,943 New
AA
68
ALPS Advisors
Colorado
$649K -$3.24K -338 -0.4%
AIA
69
AssuredPartners Investment Advisors
Florida
$639K +$4.13K +431 +0.6%
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$580K -$9.93K -1,036 -1%
State of Wisconsin Investment Board
71
State of Wisconsin Investment Board
Wisconsin
$575K +$686K +71,627 New
MC
72
Matisse Capital
Oregon
$540K +$112K +11,668 +21%
AC
73
AXQ Capital
New Jersey
$516K +$616K +64,304 New
Balyasny Asset Management
74
Balyasny Asset Management
Illinois
$496K +$592K +61,752 New
AllianceBernstein
75
AllianceBernstein
Tennessee
$489K -$174K -18,140 -30%
1 2
3
4 5

SPRY Hedge Fund Activity: Q1 2026 in Review

202 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2026, worth a combined $753M — down 27% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new SPRY positions and 25 closed out — a net gain of 16 holders — while 61 added to existing stakes and 56 trimmed.

The largest buyer was Millennium Management, adding an estimated $27M. The largest seller was Casdin Capital, exiting entirely with an estimated $18.6M sold.

  • 202 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2026, up from 189 in Q4 2025.
  • Funds reported $753M of ARS Pharmaceuticals stock for Q1 2026, down 27% quarter-over-quarter.
  • 41 funds opened new ARS Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +16 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2026 was Millennium Management, an estimated $27M added.
  • The largest ARS Pharmaceuticals seller in Q1 2026 was Casdin Capital, an estimated $18.6M sold.

Based on aggregated 13F filings for Q1 2026.